|INDICATIONS:||Non-Small Cell Lung Cancer|
|DRUG CANDIDATE:||Glesatinib (MGCD265)|
|DRIVER MUTATIONS:||MET, Axl|
A Phase 1 study evaluating the effects of glesatinib (MGCD265) as a treatment for Non-Small Cell Lung Cancer patients whose tumors carry genetic alterations of MET and Axl. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if selected mutations are present before enrolling in the clinical trial.